Anixa Biosciences Inc (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, announced on Tuesday that it has administered the second dose of its chimeric antigen receptor T-cell (CAR-T) therapy to an individual patient.

This move follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its CAR-T therapy for ovarian cancer. The study is being carried out in partnership with Moffitt Cancer Center.

Anixa and Moffitt previously received approval for a single-patient IND application, allowing the administration of a second dose to a patient whose tumour biopsy revealed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy.

After the first infusion, the subject remained stable and did not need alternative treatment and her quality of life was good, resulting in the decision to administer a second dose to further improve these positive results. These findings provide promising indications that the CAR-T therapy could serve as a successful long-term treatment option.